



Preclinical Test of  Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its 
Effectiveness for Glioblastoma 
Zahonero, C., Aguilera, P., Ramírez-Castillejo, C., Pajares, M., Bolós, M. V., 
Cantero, D., Perez-Nuñez, A., Hernández-Laín, A., Sánchez-Gómez, P., & 
Sepúlveda, J. M. (2015). Preclinical Test of  Dacomitinib, an Irreversible 
EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma. Molecular 
cancer therapeutics, 14(7), 1548–1558.  






















This	 work	 was	 supported	 by	 grants	 from	 the	 Fundación	 Mutua-madrileña	
(FMM2011/89)	to	J.M.	Sepúlveda	and	from	Ministerio	de	Economía	y	Competitividad,	
Fondo	 de	 Investigación	 Sanitaria	 (FIS):	 PI12/00775	 to	 P.	 Sánchez-Gómez	 and	
PI13/01258	to	A.	Hernández-Laín,	and	from	Ministerio	de	Economía	y	Competitividad,	















































































































































































Disgregated	 tumor	 cells	 were	 stained	 with	 anti-CD44-FITC	 (Immunotools)	 or	 AC133-PE,	
(Miltenyi)	and	analysed	by	Flow	Cytometry	(BD).		
Statistical	Analysis	
The	survival	of	nude	mice	was	analysed	by	the	Kaplan-Meier	method	and	was	evaluated	with	a	
two-sided	log-rank	test.	Student´s	t	test	or	ANOVA	test	were	performed	for	statistical	analysis	
of	in	vitro	studies.	Data	in	graphs	are	presented	as	means	±	SEM.	*	represents	a	P	value	≤0.05;	
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**	represents	a	P	value≤0.01;	***	represents	a	P	value≤0.001.	Statistical	values	of	P>0.05	were	
not	considered	significant.	
Further	information	can	be	found	in	the	Supplementary	Methods.	
	
RESULTS	
Dacomitinib	exerts	potent	inhibitory	effect	on	EGFR	amplified	GBM	Tumor	Cells		
We	first	evaluated	whether	dacomitinib	modulated	the	behavior	of	a	panel	of	GBM	cells,	
grown	in	neurosphere	culture	conditions.	The	primary	GBM	cell	lines	were	treated	with	
increasing	concentrations	of	dacomitinib	over	72	h	and	cell	viability	was	measured.	The	
cytostatic	effect	observed,	reached	a	plateau	at	very	low	concentrations	of	the	compound	and	
it	was	especially	evident	in	those	cell	lines	exhibiting	EGFR	amplification,	regardless	of	the	
presence	of	the	vIII	isoform	(Fig.	1A).		In	accordance	with	this,	dacomitinib	significantly	
inhibited	proliferation	of	all	EGFR-amplified	(EGFRamp)	GBM	cells	but	not	GBM5	and	GBM6	
that	have	no	amplification	of	the	gene	(Fig.	1B).	To	determine	whether	the	EGFR	inhibitor	
affects	the	self-renewal	capacity	of	GBM	cells,	the	neurosphere	cultures	were	maintained	in	
the	presence	of	dacomitinib	for	72	h,	before	isolating	single	cells	from	dissociated	spheres	and	
replating	them	at	semi-clonal	(2.5	cells/µL)	densities	in	the	absence	of	the	drug.	Dacomitinib	
significantly	inhibited	the	growth	of	all	the	EGFRamp	primary	lines	but	not	the	EGFR-wild	type	
(EGFRwt)	ones,	GBM5	and	GBM6	(Fig.	1C).	
Dacomitinib	inhibits	the	growth	of	EGFRamp	GBM	xenografts		
To	address	whether	the	in	vitro	effect	of	EGFR	inhibition	translated	into	a	decreased	growth	of	
GBM	cells	in	vivo,	we	injected	1	to	3.0x106	cells	into	the	flanks	of	immunodeficient	mice,	and	
when	the	tumors	reached	a	minimal	volume,	the	animals	were	separated	into	2	groups:	lactate	
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and	dacomitinib-treated	mice.	Tumor	size	was	measured	during	3	to	6	weeks,	until	animals	
were	sacrificed.	Fig.	2A	shows	how	dacomitinib	severely	impairs	the	growth	of	EGFRamp	GBM	
lines,	but	it	does	not	affect	the	growth	of	EGFRwt-GBM5.	At	the	endpoint,	there	was	a	clear	
difference	in	tumor	size	in	the	dacomitinib	treated	animals,	for	all	the	EGFRamp	lines	(Supp.	
Fig.	1).	Subsequent	analysis	of	the	tumor	tissue	indicated	that	in	the	sensitive	GBM	cell	lines	
dacomitinib	induced	a	significant	reduction	in	BrdU	incorporation	(Fig.	2B)	and	a	clear	increase	
in	the	number	of	apoptotic	cells	(Fig.	2C).	These	results	indicate	that	dacomitinib	prevents	
GBM	proliferation	and	survival,	thereby	decreasing	the	tumor	burden	of	EGFR-dependent	
GBMs.	
Effective	blockade	of	EGFR	signaling	in	dacomitinib-treated	xenografts.	
So	far,	our	results	indicate	that	the	effect	of	dacomitinib	is	EGFR-dependent	as	it	does	not	
produce	a	significant	inhibition	of	GBM5,	a	primary	cell	line	without	EGFR	amplification	and	
showing	low	levels	of	receptor	expression	(23).	In	order	to	confirm	that	dacomitinib	is	
effectively	targeting	EGFR	signaling,	we	investigated	the	phosphorylation	status	of	the	
receptor	and	its	downstream	targets	in	the	treated	tumors.	We	first	confirmed	that	several	
EGFR	tyrosine	residues	were	dephosphorylated	in	the	dacomitinib	treated	xenografts,	both	in	
GBM1	(EGFRamp)	(Fig.	3A	and	B)	and	GBM4	(EGFRamp	-vIII	positive)	(Fig.	3B).	However,	when	
we	performed	a	phosphorylation	screen	for	a	selected	panel	of	published	EGFR	pathway	signal	
transducers,	we	only	detected	a	small	decrease	in	AKT	and	S6	phosphorylation	inhibition	after	
dacomitinib	treatment	(Supp.	Fig.	2).	It	is	important	to	point	out	that	there	was	a	strong	
degree	of	variability	between	tumors	and	that	the	control	tissues	were	rich	in	necrotic	and	
inflammatory	areas	(due	to	the	big	size	of	the	tumors)	that	could	be	affecting	the	activation	of	
different	signaling	molecules.	For	that	reason,	we	decided	to	treat	two	new	cohorts	of	mice	for	
5	days.	Three	hours	after	the	last	injection	lactate	or	dacomitinib-treated	tumors	were	excised	
and	the	levels	of	activation	of	the	main	EGFR	downstream	cascades	were	analyzed	by	western	
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blot	(WB).	Fig.	3C	shows	that	there	is	a	clear	dephosphorylation	of	AKT,	ERK	and	S6,	after	
dacomitinib	treatment.	Interestingly	there	is	no	significant	effect	on	the	GBM5	xenografts.	A	
similar	result	was	observed	by	immunofluorescence	(IF)	analysis	(Fig.	3D)	confirming	that	
systemic	dacomitinib	treatment	was	able	to	inhibit	EGFR	phosphorylation	and	downstream	
signaling	in	receptor-dependent	GBMs.	
	
Dacomitinib	inhibits	intracranial	tumor	growth		
In	order	to	assay	if	dacomitinib	treatment	could	prevent	intracranial	growth	we	injected	
50.000	cells	of	GBM1	and	GBM4	in	the	striatum	of	immunodeficient	mice.	Two	(GBM4)	to	
three	(GBM1)	weeks	later,	the	mice	were	divided	into	2	groups	and	lactate	or	dacomitinib	was	
administered	systemically.	Kaplan-Meier	analysis	demonstrated	that	EGFR	inhibition	
prolonged	the	survival	of	the	GBM-bearing	animals	(Fig.	4A).	Moreover,	tumors	formed	were	
much	smaller	in	the	dacomitinib-treated	group,	as	detected	by	immunofluorescence	staining	
of	the	brain	tissue	with	a	human-specific	anti-vimentin	antibody	(Fig.	4B)	or	by	contrast-
enhanced	MRI	images	(GBM4)	(Fig.		4C).	Subsequent	analysis	of	the	tumor	tissue	confirmed	
that	there	was	a	significant	reduction	of	proliferation	(5.8	±	0.6	mitosis/field	in	lactate-treated	
animals	vs	2.5	±	0.4	in	the	dacomitinib-treated	ones)	and	a	clear	induction	of	apoptosis	in	
dacomitinib-treated	animals	(Fig.	4D).	Moreover,	we	confirmed	the	results	obtained	in	the	
flank	as	we	observed	a	strong	downregulation	of	the	phosphorylation	of	EGFR	and	its	
downstream	targets	(Fig.	4D).	All	these	results	indicate	that	systemic	dacomitinib	treatment	is	
able	to	cross	the	blood	brain	barrier	(BBB)	and	effectively	inhibits	EGFR	signaling	in	GBM	brain	
xenografts,	clearly	impairing	tumor	burden.	
Effect	of	other	mutations	in	the	response	of	GBM	primary	cells	to	dacomitinib	
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Based	on	the	literature,	it	is	not	clear	how	EGFR	mutations	affect	glioma	sensitivity	to	
dacomitinib	(21;22).	However,	the	results	presented	here	indicate	that	vIII	expressing	tumors	
are	as	sensitive	as	the	wt	EGFRamp	ones.		Interestingly,	we	were	able	to	confirm	that	
dacomitinib	is	equally	efficient	in	the	presence	of	another	EGFR	truncation	(the	vII	isoform),	
that	is	present	in	15%	of	EGFRamp	GBMs	(11).We	injected	2.0x106	cells	of	GBM7	into	the	
flanks	of	immunodeficient	mice.	When	tumors	reached	a	minimal	volume,	the	animals	were	
treated	systemically	with	lactate	or	dacomitinib,	and	tumor	size	was	measured	during	4	weeks,	
until	animals	were	sacrificed.	Figure	5A	shows	a	clear	inhibition	of	tumor	growth	in	the	
presence	of	the	drug.	
	In	order	to	test	if	chronic	activation	of	AKT	in	the	absence	of	PTEN	could	mediate	resistance	to	
EGFR	inhibition,	we	inoculated	2.0x106	cells	of	GBM2	(a	PTEN	deficient	primary	cell	line,	[25])	
into	the	flanks	of	immunodeficient	mice,	which	were	treated	as	the	previous	ones.	Fig.	5B	
shows	how	dacomitinib	produced	only	a	limited	effect	on	the	growth	of	this	EGFRamp	GBM	
line.	Alternatively,	the	animals	were	treated	for	only	5	days	and	tumors	were	excised	3	h	after	
the	last	treatment.	Subsequent	analysis	of	the	tumor	tissues	indicated	that	whereas	
dacomitinib-treated	tumors	had	statistically	significant	fewer	phospho-EGFR	positive	cells	(Fig.	
5C),	there	was	no	clear	impairment	of	AKT,	ERK	or	S6	phosphorylation	(Fig.	5C,D).	These	results	
suggest	that	in	the	absence	of	PTEN	function,	dacomitinib	can	inhibit	EGFR	tyrosine-kinase	
activity	but	this	is	not	sufficient	to	block	downstream	signaling	and	therefore	tumor	growth.	
Interestingly	the	lack	of	PTEN	did	not	prevent	the	effect	of	dacomitinib	in	vitro	(Fig.	1)	
suggesting	that	in	the	tumors	there	are	other	signals	that	compensate	the	inhibition	of	EGFR	in	
the	absence	of	PTEN	function.	
Dacotiminib	reduces	the	aggressiveness	and	the	stemness	of	EGFRamp	GBMs	
Histochemical	analysis	of	the	flank	xenografts	indicated	an	almost	complete	disappearance	of	
mitosis	and	a	change	in	the	cellular	morphology	that	suggested	a	less	aggressive	and	more	
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differentiated	state	on	the	dacomitinib-treated	tumors	(Fig.	6A).	We	therefore	performed	an	
RT-PCR	analysis	of	several	stem-cell-related	molecules.	Although	there	was	a	high	degree	of	
variability	between	tumors,	we	detected	a	clear	inhibition	of	some	of	them	in	the	EGFRamp	
xenografts	that	had	been	treated	with	dacomitinib	in	the	five	days	schedule	(Supp.	Fig.	3)	and	
even	more	after	the	long	term	treatment	(Fig.	6B	and	Supp.	Fig.	4)	However,	we	were	not	able	
to	detect	any	clear	increase	in	differentiation	markers	in	the	treated	tumors	(Supp.	Fig.	4).	
Interestingly	we	observed	a	significant	decrease	in	the	number	of	cells	expressing	stem	cell	
related	markers	(CD44	and	CD133)	at	cell	surface	in	EGFRamp	tumors	that	had	been	treated	
with	dacomitinib,	but	not	in	the	EGFRwt	ones	(Figure	6C).	These	results	suggest	that	EGFR	
inhibition	is	inducing	the	loss	of	stem-cell	features	and	that	this	could	be	the	reason	for	the	
less	aggressive	behavior	of	dacomitinib-treated	tumors.	However,	EGFR	inhibition	does	not	
seem	to	provoke	the	terminal	differentiation	of	the	cells	(Supp.	Fig.	5).	In	fact	the	effect	of	
dacomitinib	is	reversible	as	tumor	growth	relapsed	after	drug	removal	(Fig.	6D),	suggesting	
that	continuous	regimes	should	be	necessary	to	control	GBM	growth.		
	
DISCUSSION		
	 Treatment	options	for	GBM	with	standard	cytotoxic	agents	are	unsatisfactory,	thus	the	
development	of	effective	therapeutic	strategies	is	urgently	needed.	EGFR	is	amplified	or	
mutated	in	a	large	number	of	glioma	patients,	but	first	generation	of	EGFR	inhibitors	have	
failed	to	show	a	clinical	benefit.	In	this	study	we	assessed	the	activity	of	dacomitinib,	an	
irreversible	PAN-HER	inhibitor	that	is	being	tested	in	recurrent	GBM,	in	a	panel	of	primary	
GBM	cells	grown	in	vitro	(as	neurospheres)	and	in	vivo	using	a	nude	mice	xenograft	model.		
	 Our	in	vitro	results	indicate	that	dacomitinib	acts	in	a	specific	way	as	it	inhibits	the	
proliferation	and	viability	of	the	EGFRamp	but	not	the	EGFRwt	GBM	primary	cell	lines.	Two	
other	studies	have	recently	demonstrated	that	the	drug	is	able	to	inhibit	EGFR	phosphorylation	
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and	to	reduce	viability	of	different	GBM	cells	(21;22).	Zhu	and	coworkers	have	indicated	that	
GBM	cells,	forced	to	overexpress	the	vIII	mutant	isoform	of	EGFR,	do	not	respond	so	well	to	
dacomitinib	(21).	However,	our	data	show	that	all	EGFRamp	GBMs	are	sensitive	to	the	drug,	
regardless	of	the	presence	of	EGFR	deletions.	This	would	be	in	agreement	with	the	other	
authors	that	have	postulated	that	tumors	harboring	certain	point	mutations,	as	well	as	the	vIII	
deletion,	would	be	more	responsive	to	dacomitinib	(22).	In	fact,	the	presence	of	EGFRvIII,	in	a	
wild-type	PTEN	context,	had	been	associated	with	GBM	response	to	erlotinib	(15),	although	
this	could	not	be	confirmed	in	subsequent	trials	(25).	Retrospective	analysis	of	the	two	current	
phase	II	clinical	trials	would	help	to	solve	these	discrepancies.		
	 GBM	cells	grown	in	the	absence	of	serum	are	enriched	in	the	so-called	cancer	stem	
cells	(CSCs)	(26).	These	cells	have	a	stronger	self-renewal	capacity	than	the	rest	of	the	tumor,	
which	can	be	tested	in	a	clonogenic	assay.	Our	results	indicate	that	dacomitinib	clearly	impairs	
the	self-renewal	of	GBM-CSCs,	but	only	if	they	show	EGFR	amplification.	Moreover,	we	have	
confirmed	the	effect	of	EGFR	inhibition	in	vivo	as	systemic	dacomitinib	treatment	dramatically	
impairs	the	growth	of	EGFRamp	tumors.	The	posterior	analysis	indicated	that	dacomitinib	
induced	an	increase	in	the	number	of	apoptotic	cells.	However,	cell	death	does	not	seem	to	be	
the	main	response	of	GBM	cells	as	the	effect	of	the	drug	is	reversible.	Thus,	when	dacomitinib	
was	removed,	tumors	restarted	to	grow	rapidly	demonstrating	the	specific	effect	of	the	
compound	and	suggesting	that	continuous	treatment	should	be	needed	to	prevent	tumor	
growth	in	patients.	Interestingly,	we	have	observed	that	EGFR	dephosphorylation	provokes	the	
accumulation	of	the	receptor	(see	Fig.	3A	as	an	example).	As	EGFR	could	be	exerting	some	
survival	function	in	a	kinase	independent	manner	(9)	which	may	represent	an	undesirable	
secondary	effect	of	EGFR	kinase	inhibitors	and	it	could	contribute	to	the	reversibility	of	its	
effect.	
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	 Histological	analysis	suggested	that	tumors	exposed	to	dacomitinib	have	a	more	
differentiated	phenotype	with	less	aggressive	behavior.	This	is	in	agreement	with	the	
downregulation	of	several	stem	cell-related	markers	in	dacomitinib-treated	tumors.		EGFR	
expression	is	a	marker	of	proliferating	neural	stem	cells	and	progenitors	(27).	Indeed,	the	
presence	of	the	receptor	in	the	membrane	marks	a	highly	aggressive	subpopulation	of	GBM-
CSCs	(28)	and	EGFR	signaling	has	been	linked	to	the	expression	of	stem	cell	features	in	GBMs	
(29).	More	recently,	it	has	been	demonstrated	that	EGFR	is	downregulated	upon	GBM	
differentiation	and	that	EGFR	signaling	blockade	leads	to	decreased	tumorigenic	and	stem	cell-
like	potential	of	GBM	neurospheres	(30).	Therefore,	dacomitinib	could	be	targeting	specifically	
the	GBM-CSC	population.	However,	we	do	not	observe	a	clear	upregulation	of	terminally	
differentiated	neural	cells	upon	EGFR	inhibition,	and	this	could	also	explain	why	the	effects	of	
the	drug	are	reversible	and	tumors	restart	when	the	treatment	stops.		
	 Two	of	the	most	consistently	stem-cell-related	downregulated	molecules	after	EGFR	
inhibition	were	LIF	and	IL11.	These	two	cytokines	have	been	associated	with	the	maintenance	
of	self-renewal	in	normal	and	tumorigenic	stem	cells	(31-33).	These	results	suggest	that	EGFR	
could	be	modulating	the	maintenance	of	GBM	stemness	in	a	paracrine	way	and	could	correlate	
with	the	mosaic	distribution	of	EGFR	amplification	and	vIII	expression	in	the	tumors	(34).	
Furthermore,	part	of	the	tumorigenic	capacity	of	EGFR	in	GBM	could	be	mediated	by	the	
secretion	of	cytokines	(including	LIF)	(35).	Interestingly	LIF	secretion	mediates	also	the	
tumorigenic	potential	of	TGFβ	in	GBMs	(33)	suggesting	a	possible	crosstalk	between	the	two	
signaling	pathways	in	such	tumors,	as	it	has	been	proposed	by	others	(36).	Therefore,	a	
possible	synergism	between	dacomitinib	and	TGFβ inhibitors,	currently	under	development	for	
the	treatment	of	GBM,	could	be	envisioned.	
	 There	has	been	doubts	about	the	capability	of	the	EGFR-TKI	to	reach	the	brain	
parenchyma	and	to	cross	the	BBB	(37;38).	Here,	we	demonstrate	that	dacomitinib	can	reach	
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the	brain	and	prevent	intracranial	growth,	confirming	the	results	obtained	in	the	flank.	In	the	
case	of	gefitinib,	very	high	concentrations	of	the	drug	were	found	in	the	resected	tumors,	
together	with	an	efficient	EGFR	dephosphorilation.	However,	the	clinical	results	were	
discouraging,	which	seemed	to	correlate	with	the	inefficient	dephosphorylation	of	the	EGFR	
downstream	targets	in	vivo	(both	in	patients	and	in	the	xenografts	models)	(5).		Our	data	with	
dacomitinib	indicates	in	turn	that	this	compound	can	efficiently	inhibit	tumor	growth	because	
it	can	target	the	EGFR	signaling	pathway,	provoking	the	dephosphorylation	of	the	main	EGFR	
downstream	cascades.	This	effect	was	not	observed	in	the	EGFRwt	tumors.	These	findings	are	
in	accordance	with	those	found	by	Zhu	and	Shah	that	demonstrated	an	inhibition	on	
downstream	molecules	such	as	PLC.	However,	they	only	tested	that	in	vitro	(21).	Although	
these	authors	suggest	that	multiple	genetic	lesions	determine	GBM	response	to	dacomitinib	in	
fact,	they	show	that	the	only	sensitive	GBM	cell	line	to	low	doses	of	the	compound	is	that	with	
EGFR	amplification.		Although	dacomitinib	can	inhibit	HER2	and	HER4	it	does	not	seem	to	be	
relevant	for	GBM	blockade	as	we	could	not	detect	expression	of	those	receptors	in	any	of	the	
responsive	lines	(data	not	shown),	in	agreement	with	other	observations	(39;40).	Moreover,	
HER2	is	not	amplified	in	GBMs	(41).	Nevertheless,	we	also	find	that	in	the	absence	of	PTEN	
function	dacomitinib	loses	part	of	its	antitumor	capacity	in	vivo.	However,	we	cannot	discard	
that	additional	genetic	alteration	in	GBM2	cells	could	be	affecting	the	response	to	dacomitinib.	
Moreover,	certain	extracellular	mutations	in	EGFR	could	make	the	tumors	responsive	to	
dacomitinib,	even	if	PTEN	is	mutated	(like	in	the	case	of	U87	cells)	(22).	Altogether,	these	
results	reinforce	the	notion	that	the	characterization	of	EGFR	status	and	PTEN	function	is	
fundamental	to	predict	GBM	response	to	dacomitinib	(14).	Another	corollary	to	all	these	data	
would	be	that	PI3K/mTOR	inhibitors	could	synergize	with	dacomitinib,	as	it	has	already	been	
tested	in	glioma	cell	lines	(21).			
	 In	conclusion,	the	results	presented	here	allow	us	to	propose	that	dacomitinib	could	
be	an	active	drug	in	GBM	since	it	is	able	to	inhibit	tumor	growth	in	vitro	and	in	vivo	of	
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EGFRamp	tumors	and	it	is	able	to	reach	the	brain	parenchyma.	The	growth	inhibition	is	based	
on	the	dephosphorylation	of	the	downstream	effectors	and	a	possible	paracrine	effect	
mediated	by	stem	cells-related	cytokines.	Moreover,	based	on	our	data	dacomitinib	treatment	
should	be	given	in	a	continuous	regime	and	would	be	effective	even	in	the	presence	of	the	
EGFR	mutant	isoforms.	Furthermore,	the	presence	of	an	active	PTEN	activity	should	be	
checked	as	a	predictive	marker.	Current	clinical	trials	testing	dacomitinib	in	GBM	will	shed	light	
on	these	affirmations	but	dacomitinib	seems	to	be	a	promising	treatment	for	newly	diagnosed	
glioblastoma,	alone	or	in	combination	with	cytotoxic	agents,	molecules	that	could	favor	EGFR	
degradation	and	TGFβ	or	PI3K/mTOR	inhibitors.	It	will	be	particularly	relevant	to	determine	if	
those	synergistic	therapies	would	induce	then,	an	irreversible	tumor	growth	inhibition.	
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FIGURE	CAPTIONS	
Figure	1.	Dacomitinib	impairs	GBM	growth	and	self-renewal	in	EGFRamp	cell	lines.	A,	B,	GBM	
primary	cells	were	incubated	for	3	days	in	the	presence	of	increasing	concentrations	of	
dacomitinib	and	cell	viability	(A)	or	BrdU	incorporation	(B)	was	measured.	C,	formation	of	
secondary	spheres	after	pretreatment	with	dacomitinib	(25	and	50	nM)	or	DMSO	for	3	days.	
Representative	phase-contrast	images	of	the	primary	GBM	lines	used	and	their	EGFR	genomic	
status	are	shown	in	the	bottom.	*	P	≤	0.05,	**	P	≤	0.01,	***	P	≤	0.001	
Figure	2.	Decreased	GBM	tumor	burden	in	the	presence	of	dacomitinib.	A,	GBM	primary	cells	
(1	to	3x106)	were	injected	into	the	flanks	of	nude	mice.	When	tumors	reached	a	visible	size	
mice	were	treated	orally	with	daily	doses	of	dacomitinib	(15mg/Kg/day,	5	days/week)	or	
vehicle	(lactate)	and	tumor	size	was	measured	once	every	4-5	days.	Graphs	represent	the	fold	
increase	in	tumor	volume.	B,	number	of	mitotic	cells	per	field	in	the	flank	tumors.	C,	number	of	
Caspase	3	positive	cells	per	field	in	the	flank	tumors.	*	P	≤	0.05,	**	P	≤	0.01,	***	P	≤	0.001	
Figure	3.	Dacomitinib	blocks	EGFR	phosphorylation	and	signaling	in	vivo	in	EGFRamp	GBMs.	
The	phosphorylation	status	of	EGFR	after	long-term	treatment	with	lactate	or	dacomitinib	was	
analyzed	by	WB	(A)	and/or	IF	(B)	in	GBM1	and	GBM4	tumors.	A,	relative	protein	levels	(a.u.)	
are	represented	in	the	right	panel.	ACTIN	was	used	as	a	loading	control.	B,	quantification	of	the	
fluorescence	intensity	(a.u.)	is	shown	in	the	panels.	WB	(C)	or	IF	(D)	analysis	of	EGFR	
downstream	signaling	after	short-term	treatment	of	flank	tumors.	C,	relative	phosphorylation	
levels	(a.u.)	are	represented	in	the	right	panels.	GAPDH	was	used	for	normalization.	D,	
quantification	of	the	fluorescence	intensity	(a.u.)	is	shown	in	the	right	graphs.	Scale	bar,	50µm	
in	B	and	D	(bigger	panels),	10µm	in	D	(magnified	pictures).		*	P	≤	0.05,	**	P	≤	0.01,	***	P	≤	
0.001	
Figure	4.	Intracranial	GBM	growth	is	impaired	by	systemic	Dacomitinib	treatment.	50,000	
GBM1	(A)	and	GBM4	(B)	cells	were	implanted	intracranially	into	nude	mice.	Two	to	three	
weeks	later	(arrow),	the	animals	started	to	receive	intragastric	injections	of	vehicle	(lactate)	or	
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dacomitinib	(15mg/Kg/day,	5days/week).	Animal	survival	was	evaluated	using	a	Kaplan-Meier	
survival	curve	and	the	differences	in	survival	times	were	analyzed	with	a	log-rank	test	(n=5).	
The	images	on	the	right	show	representative	vimentin	staining	of	tumors	formed.		C,	
representative	contrast-enhanced	MRI	images	at	different	time	points	after	GBM4	brain	
injection.	D,	representative	images	of	Activated	Caspase	3	(Act	Casp3),	and	phosphorylated	
EGFR,	ERK,	AKT	and	S6	staining	in	vehicle	and	dacomitinib-treated	tumor	tissues.	
Quantification	of	the	fluorescence	intensity	(a.u.)	is	shown	in	the	panels.	Scale	bar,	200µm	in	
B;	50µm	in	D.	
Figure	5.	Effect	of	other	mutations	in	the	response	of	GBM	tumors	to	dacomitinib.	GBM2	(A)	
or	GBM7	(B)	primary	cells	(1	to	3x106)	were	injected	into	the	flanks	of	nude	mice.	When	
tumors	reached	a	visible	size,	mice	were	treated	orally	with	daily	doses	of	dacomitinib	
(15mg/Kg/day,	5	days/week)	or	vehicle	(lactate)	and	tumor	size	was	measured	once	every	4-5	
days	until	the	animals	were	sacrificed.	IF	(C)	or	WB	(D)	analysis	of	the	EGFR	pathway	status	
after	short	term	(5	days)	treatment	of	GBM2	injected	animals.	Quantification	of	the	
fluorescence	intensity	(a.u.)	is	shown	in	the	panels	(C).	D,	relative	phosphorylation	levels	(a.u.)	
are	represented	in	the	right	panels.	ACTIN	was	used	for	normalization.		Scale	bar,	50µm.	
Figure	6.	EGFR	blockade	induces	a	reversible	differentiation	of	GBM	cells.	A,	representative	
images	of	hematoxylin-eosin	stainings	of	GBM1	and	GBM4	flank	tumors	after	long-term	
treatment.	B,	qRT-PCR	analysis	of	stem	cell-related	genes	in	GBM1	and	GBM4	tumors.	The	
level	of	HPRT	was	used	for	normalization.	C,	analysis	by	cell	cytometry	of	stem	cell-related	
surface	markers	after	tumor	dissociation.	D,	After	4	weeks	of	treatment	the	animals	were	left	
untreated	and	the	recovery	of	the	tumors	was	analyzed.	Scale	bar,	10µm. *	P	≤	0.05,	**	P	≤	
0.01	
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